Showing 2811-2820 of 6036 results for "".
- Hoya Vision Care and Myopia Profile Training the Visionaries of the Futurehttps://modernod.com/news/hoya-vision-care-and-myopia-profile-training-the-visionaries-of-the-future/2479370/Hoya Vision Care announced the roll out of a suite of co-created certified training courses to educate, inform and empower eye care professionals (ECPs) to prescribe spectacle lenses for children in the global fight t
- Opthea’s OPT-302 Granted FDA Fast Track Designation for Wet AMDhttps://modernod.com/news/optheas-opt-302-granted-fda-fast-track-designation-for-wet-amd/2479360/Opthea has announced FDA has granted Fast Track designation for the company’s VEGF-C/-D ‘trap’ inhibitor, OPT-302, in combination with anti-VEGF-A therapy for the treatment of patients with wet age-related macular degeneration (AMD). The FDA’s Fast Track pro
- Horizon Therapeutics Partners With Olympic Gold Medalist Gail Devers to Raise Awareness of Graves’ Disease and Symptoms of Thyroid Eye Disease (TED)https://modernod.com/news/horizon-therapeutics-partners-with-olympic-goldmmedalist-gail-devers-to-raise-awareness-of-graves-disease-and-symptoms-of-thyroid-eye-disease-ted/2479357/For Graves’ Disease Awareness Month in July, Horizon Therapeutics is teaming up with track star and three-time Olympic gold medalist Gail Devers, who has been living with Graves’ disease and symptoms of Thyroid Eye Disease (TED) for more than 30 years. Horizon and Ms. Devers are collaborating wit
- Mikajaki Partners With Segula Technologies to Develop Ophthalmic Diagnosis Devicehttps://modernod.com/news/mikajaki-partners-with-segula-technologies-to-develop-ophthalmic-diagnosis-device/2479353/Swiss startup Mikajaki is teaming up with engineering group Segula Technologies to develop the first operational series of EyeLib, an automated diagnostic station that aims to revolutionize the management of the growing number of patients with vision disorders, according to a company news release
- Contact Lens Institute Unveils Nationwide “See Tomorrow Campaign;” Industry Launch Event Slated for July 22https://modernod.com/news/contact-lens-institute-unveils-nationwide-see-tomorrow-campaign-industry-launch-event-slated-for-july-22/2479347/A new professional and consumer initiative from the Contact Lens Institute (CLI) is poised to reveal insights about how patient psyches surrounding vision, health care and their lives have changed over the course of the pandemic—and the ensuing opportunities for the optometry community. The CLI <
- Oasis TEARS PF PLUS Preservative-Free Lubricant Eye Drops Now Delivered in a Bottlehttps://modernod.com/news/oasis-tears-pf-plus-preservative-free-lubricant-eye-drops-now-delivered-in-a-bottle/2479338/Oasis Medical is launching Oasis TEARS PF PLUS preservative-free lubricant eye drops delivered in a 10mL bottle for multiuse. Lubricant eye drops, which are packaged in traditional multi-use bottles, contain preservatives to prevent microbial growth. Preservative-free lubricant eye drops a
- ASCRS: Insurance Company Policy Delays Sight-Restoring Surgery, Puts Patients in Jeopardyhttps://modernod.com/news/ascrs-insurance-company-policy-delays-sight-restoring-surgery-puts-patients-in-jeopardy/2479334/The decision by Aetna to require preauthorization of all cataract surgery procedures went into effect July 1. In a news release, ASCRS said it is opposed to the preauthorization policy, stating it will create delays i
- PYC Therapeutics Announces Preclinical Results Demonstrating VP-002 Program’s Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophyhttps://modernod.com/news/pyc-therapeutics-announces-comprehensive-preclinical-results-demonstrating-vp-002-programs-potential-as-the-first-disease-modifying-therapy-for-autosomal-dominant-optic-atrophy/2479330/PYC Therapeutics released a summary of preclinical findings supporting the potential of PYC’s VP-002 program as the first disease-modifying therapy for patients suffering from Autosomal Dominant Optic Atrophy (ADOA). PYC’s PPMO technology used in the VP-002 program significantly increases levels
- FDA Accepts Application for Genentech’s Port Delivery System with Ranibizumab (PDS) for Treatment of Wet AMDhttps://modernod.com/news/fda-accepts-application-for-genentechs-port-delivery-system-with-ranibizumab-pds-for-treatment-of-wet-amd/2479322/Genentech announced that the FDA has accepted the company’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ranibizumab (PDS) for the treatment of wet age-related macular degeneration (AMD). If approved, PDS would be a first-of-its-kind therapeutic approa
- Bausch + Lomb Expands Parameters for Bausch + Lomb Ultra Multifocal for Astigmatism Contact Lenseshttps://modernod.com/news/bausch-lomb-expands-parameters-for-bausch-lomb-ultra-multifocal-for-astigmatism-contact-lenses/2479319/Bausch + Lomb announced the US launch of expanded parameters for Bausch + Lomb ULTRA Multifocal for Astigmatism contact lenses. The expansion, which includes the addition of -2.25D and -2.75D cylinder power parameters, will be part of the company’s standard offering of the lens and will ext